# TroFuse-005 (NCT06132958)

> Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06132958
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Endometrial Cancer
- Interventions: Sacituzumab tirumotecan; Doxorubicin; Paclitaxel; Nab-paclitaxel; Rescue medications
- Enrollment: 710
- Primary outcome: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18
- YouTube: 2
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=trofuse-005-nct06132958

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06132958", "email": "<work email>"}; the inbox owner confirms by the emailed link.